Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 EUR | -.--% | -36.71% | -79.47% |
05-01 | Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc. | CI |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
Sales 2021 | 3.6 3.31 282.16 | Sales 2022 | 2.51 2.32 197.32 | Capitalization | 14.29M 13.18M 1.12B |
---|---|---|---|---|---|
Net income 2021 | -237M -219M -18.6B | Net income 2022 | -70M -64.55M -5.49B | EV / Sales 2021 | 53,517,059 x |
Net cash position 2021 | 45.01M 41.5M 3.53B | Net cash position 2022 | 10.16M 9.36M 797M | EV / Sales 2022 | 1,644,636 x |
P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
1 week | -36.71% | ||
1 month | -92.31% | ||
3 months | -90.38% | ||
6 months | -94.74% | ||
Current year | -79.47% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Ronald Barliant
BRD | Director/Board Member | 78 | 06/01/16 |
1st Jan change | Capi. | |
---|---|---|
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- HGENQ Stock
- 0KB2 Stock